A Phase I Study of IGN523 in Subjects With Relapsed or Refractory AML

NCT02040506 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

19

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Myelogenous Leukemia
Acute Myeloid Leukemia

Interventions

DRUG: IGN523

Sponsor

Igenica Biotherapeutics, Inc.